沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09996 沛嘉医疗-B

未开盘 04-10 16:09:20

6.660

+0.400

+6.39%

最高6.700	最低6.290	成交量209.60万
今开6.410	昨收6.260	日振幅6.55%
总市值44.76亿	流通市值44.76亿	总股本6.72亿
成交额1,379万	换手率0.31%	流通股本6.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09996","market":"HK","secType":"STK","nameCN":"沛嘉医疗-B","latestPrice":6.66,"timestamp":1775808560010,"preClose":6.26,"halted":0,"volume":2096000,"delay":0,"changeRate":0.06389776357827481,"floatShares":672000000,"shares":672000000,"eps":-0.35025369220526953,"marketStatus":"未开盘","change":0.4,"latestTime":"04-10 16:09:20","open":6.41,"high":6.7,"low":6.29,"amount":13790560,"amplitude":0.065495,"askPrice":6.67,"askSize":12000,"bidPrice":6.63,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.35025369220526953,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":0,"adr":0,"listingDate":1589472000000,"exchange":"SEHK","adjPreClose":6.26,"openAndCloseTimeList":[[1775784600000,1775793600000],[1775797200000,1775808000000]],"volumeRatio":1.2920724940800359,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09996","defaultTab":"news","newsList":[{"id":"2626517211","title":"1900亿“医械茅”，净利润大降30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626517211","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626517211?lang=zh_cn&edition=full","pubTime":"2026-04-12 18:08","pubTimestamp":1775988480,"startTime":"0","endTime":"0","summary":"　　近日，中国医疗器械行业的“一哥”，迈瑞医疗在2025年遭遇了上市以来的首次年度营收下滑。　　年报数据显示，迈瑞医疗全年实现营业收入332.82亿元，同比下降9.38%；归母净利润81.36亿元，同比下降30.28%；扣非归母净利润80.69亿元，同比下降29.48%。Wind数据统计，截至2026年4月9日，139家A股医疗器械企业中已有30家发布了2025年年报，整体实现营业收入708.58亿元，同比下降2.20%；实现归母净利润142.58亿元，同比下降19.37%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2026-04-12/doc-inhufuxw6411367.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-04-12/doc-inhufuxw6411367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09997","BK1100","BK1583","SINA","BK1222","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626548179","title":"关税高墙下，中国医疗器械企业的“韧性答卷”｜2026智·跃迁","url":"https://stock-news.laohu8.com/highlight/detail?id=2626548179","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626548179?lang=zh_cn&edition=full","pubTime":"2026-04-12 12:57","pubTimestamp":1775969838,"startTime":"0","endTime":"0","summary":"4月9日，第93届中国国际医疗器械博览会（CMEF）在上海国家会展中心拉开帷幕。本届展会以“创新聚变，无限跃迁”为主题，汇聚了来自全球30余个国家和地区的近5000家品牌企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604123702126522.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604123702126522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1100","BK1222","159883","BK1574","09996","09997","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626556196","title":"科华生物最新公告：两款产品获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2626556196","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626556196?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:50","pubTimestamp":1775814655,"startTime":"0","endTime":"0","summary":"科华生物(002022.SZ)公告称，公司及控股子公司苏州天隆近日分别收到国家药监局颁发的医疗器械注册证。其中，苏州天隆的“EB病毒核酸测定试剂盒(PCR-荧光探针法)”获证，用于体外定量检测人全血或血浆中的EB病毒DNA核酸；公司的“解脲脲原体核酸检测试剂盒(PCR-荧光法)”获证，用于体外定性检测男性尿道拭子、女性宫颈拭子样本中的解脲脲原体核酸。上述注册证有效期均为5年。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000031074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","159883","BK1574","BK1222","002022","BK0046","09997","BK0028","BK0239","BK1100","09996","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626195160","title":"华大智造(688114.SH)子公司基因测序仪产品获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2626195160","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626195160?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:28","pubTimestamp":1775813295,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华大智造(688114.SH)发布公告，公司全资子公司深圳华大智造生物电子科技有限公司的基因测序仪产品于近日取得了中华人民共和国医疗器械注册证。该产品采用联合探针锚定聚合测序技术，在临床上用于对来源于人体样本的脱氧核糖核酸(DNA)和核糖核酸(RNA)进行测序，以检测基因序列，这些基因序列可用于辅助诊断疾病或疾病易感性。该仪器在临床上仅限于与国家药品监督管理部门批准的体外诊断试剂以及软件配合使用，不用于人类全基因组的测序或从头测序。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","BK1100","BK1574","BK1222","09996","BK1583","09997","159883","688114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626605941","title":"医疗器械鏖战同质化，AI能否成为“破局者”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2626605941","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626605941?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:02","pubTimestamp":1775808120,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛上海报道近日，第93届中国国际医疗器械博览会（CMEF）在上海启幕。在这场全球医疗行业瞩目的盛会上，一个现象尤为突出：几乎每一家参展商都在谈AI，从大型影像设备到家用便携式器械，“AI+”成为展馆里最高频的标签。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103701120024.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701120024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AGIX","BK1222","BK1574","CHAT","09997","ARTY","AIPO","159883","09996","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626167474","title":"中信建投：中国医疗器械成长逻辑重塑 关注出海与并购趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2626167474","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626167474?lang=zh_cn&edition=full","pubTime":"2026-04-10 15:44","pubTimestamp":1775807078,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，中国医疗器械行业成长逻辑已经逐步从国产替代转为创新与国际化，医疗器械产品研发也从过往的跟随为主逐步转向并跑乃至领跑。出海与并购趋势：医疗器械行业自主出海较多，BD及并购事件逐步增加立足国内的人口数量、医生经验、临床数据、工程师红利和产业链优势，中国医疗器械创新正在逐步走向全球。部分国内器械公司被海外器械龙头收购后有望加速出海。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK1100","BK1574","601066","BK1222","BK1583","09997","BK0276","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626100164","title":"观察｜医疗器械进入AI深水区，行业比拼真实落地能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2626100164","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626100164?lang=zh_cn&edition=full","pubTime":"2026-04-10 14:42","pubTimestamp":1775803320,"startTime":"0","endTime":"0","summary":"AI（人工智能）在医疗器械行业正在从概念展示走向真实落地。4月9日至4月12日，第93届中国国际医疗器械博览会（CMEF）在上海举办。作为全球医疗器械行业的创新风向标，本届展会总规模超32万平方米，聚集了全球20余个国家和地区的近5000家品牌企业，数万款行业新品集中亮相。CMEF现场过去几年，AI一直是医疗器械行业以及CMEF展会期间的热词。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103701031036.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701031036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AIPO","AGIX","CHAT","BK1222","BK1574","159883","09996","09997","ARTY","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626616111","title":"河北省药监局：6批次医疗器械抽检不合格，涉宝塔医疗、胜健医疗等","url":"https://stock-news.laohu8.com/highlight/detail?id=2626616111","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626616111?lang=zh_cn&edition=full","pubTime":"2026-04-10 14:26","pubTimestamp":1775802402,"startTime":"0","endTime":"0","summary":"蓝鲸新闻4月10日讯，河北省药品监督管理局于2026年4月7日发布《2025年国家医疗器械监督抽检不合格产品处置情况公告 》，通报6批次医疗器械抽检不合格。涉及产品包括医用防护口罩、半导体激光治疗仪、牙科钴铬支架合金及聚氨酯泡沫敷料等，主要问题为不符合相关强制性国家标准或技术要求，具体涵盖物理性能、材料成分、安全指标等方面不达标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775802317202792353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1222","09996","BK1574","159891","09997","BK1583","BK1100","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626157150","title":"港股异动 | 沛嘉医疗-B(09996)盘中涨超6% GeminiOne TEER系统已成功完成美国EFS中的首例患者植入","url":"https://stock-news.laohu8.com/highlight/detail?id=2626157150","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626157150?lang=zh_cn&edition=full","pubTime":"2026-04-10 10:35","pubTimestamp":1775788516,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，沛嘉医疗-B盘中涨超6%，截至发稿，涨3.83%，报6.5港元，成交额352.34万港元。消息面上，4月9日，沛嘉医疗-B发布公告，GeminiOne经导管缘对缘修复系统于美国食品药品监督管理局早期可行性研究中的首例患者植入已成功完成。公司第三代长效干瓣TaurusNXT已于2025年12月获NMPA受理，GeminiOne TEER已在中国递交注册申请并同步推进欧盟MDR CE申请，HighLife TMVR注册临床持续推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","BK4585","159891","BK1574","BK1583","BK1100","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626181579","title":"锚定3年200亿元销售目标，京东健康全面发力“AI+医疗器械”","url":"https://stock-news.laohu8.com/highlight/detail?id=2626181579","media":"上观新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626181579?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:25","pubTimestamp":1775733947,"startTime":"0","endTime":"0","summary":"4月9日，在第93届中国国际医疗器械博览会（CMEF）上，京东健康升级“AI+医疗器械”战略，宣布将依托京东JoyAI大模型能力，通过接入京东附身智能JoyInside推动医疗器械从“功能工具”向“主动关怀的智能伙伴”的价值跃迁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699799821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","LU0051755006.USD","BK1222","BK1589","CHAT","09997","AIPO","BK1142","BK1247","AGIX","BK1100","86618","159883","BK1515","BK1591","SGXZ62798434.SGD","SGXZ86797644.SGD","06618","BK1583","BK1571","BK1615","09996","LU0456827905.SGD","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626185210","title":"沛嘉医疗-B(09996)：GeminiOne® 经导管缘对缘修复系统美国早期可行性研究的首例患者植入","url":"https://stock-news.laohu8.com/highlight/detail?id=2626185210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626185210?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:40","pubTimestamp":1775731253,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B(09996)公布，GeminiOne®经导管缘对缘修复(TEER)系统于美国食品药品监督管理局(FDA)早期可行性研究(EFS)中的首例患者植入已成功完成。该手术由HCA Healthcare旗下Los Robles Regional Medical Center结构性心脏病介入与临床研究主任、加州大学洛杉矶分校大卫 • 格芬医学院临床医学教授Saibal Kar教授主刀完成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1100","09996","BK1583","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626907720","title":"天保基建：已取得医疗器械经营许可等资质","url":"https://stock-news.laohu8.com/highlight/detail?id=2626907720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626907720?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:57","pubTimestamp":1775725026,"startTime":"0","endTime":"0","summary":"证券之星消息，天保基建04月09日在投资者关系平台上答复投资者关心的问题。2025年度天保医药科技公司在医疗器械、中医药业务方面已取得营业收入716万元。未来将继续巩固核心伙伴合作，加深医疗器械、中药材领域业务合作的深度与广度，挖掘新的营收增长点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900026637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1222","BK0013","000965","159883","09997","BK1583","BK1574","BK1100","09996","BK0273","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626920909","title":"河南省药监局：12批次化妆品抽检不合格，涉Rouzi柔姿、首席魔发师等品牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2626920909","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626920909?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:01","pubTimestamp":1775718101,"startTime":"0","endTime":"0","summary":"蓝鲸新闻4月9日讯，2026年4月7日，河南省药品监督管理局发布《化妆品抽样检验结果公告 》，通报2025年对11类化妆品开展抽检中发现的12批次不符合规定产品。目前，省药监局已将相关情况通报属地监管部门，依法依规开展核查处置，责令企业停止销售、下架召回并立案调查。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775717572805208787","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["09996","BK1574","BK1222","BK1100","BK1583","09997"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154957558","title":"沛嘉医疗-B2026年3月股份变动月报：无新增发行，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1154957558","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154957558?lang=zh_cn&edition=full","pubTime":"2026-04-08 12:22","pubTimestamp":1775622139,"startTime":"0","endTime":"0","summary":"2026年4月8日，沛嘉医疗有限公司披露截至2026年3月31日的股份变动月报。公告显示，公司本月并无新增发行股份或回购注销活动，整体股本结构维持不变。根据报告，公司注册股本维持为1,000,000,000股，面值每股USD 0.0001，总注册股本USD 100,000。已发行股份总数继续保持在672,060,659股，库存股份数量为0股。本月内，公司购股权计划亦未发生授出、行使、注销或失效的变动。其中，第一项购股权计划维持29,428,920份，第二项购股权计划维持4,571,162份。该月报由公司董事张一签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625999270","title":"博济医药：公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2625999270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625999270?lang=zh_cn&edition=full","pubTime":"2026-04-08 11:34","pubTimestamp":1775619242,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药04月07日在投资者关系平台上答复投资者关心的问题。博济医药回复：您好，目前公司没有与药石科技合作，公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务，包括：临床前研究服务、临床研究服务、其他咨询服务以及CDMO服务，其中临床研究服务为公司最主要的业务板块，占公司整体营业收入80%以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800014274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK1100","BK1574","BK1222","BK1583","09997","BK0216","09996","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937512","title":"贝康医疗-B(02170)：受精培养液和囊胚培养液获国家药监局颁发医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937512","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625937512?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:29","pubTimestamp":1775561354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布公告，本公司Gems系列两款核心培养液产品 — 受精培养液和囊胚培养液于2026年4月2日双双获得国家药品监督管理局颁发的三类医疗器械注册证。此次获证的受精培养液与囊胚培养液，与今年2月已获批的Geri胚胎培养液、 2025年获批的胚胎处理液，共同构成了覆盖“受精→卵裂胚培养→囊胚培养”全流程的Gems全品系培养液矩阵。受精培养液专为卵母细胞和精子提供适宜的受精环境，以促进受精。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02170","09997","09996","BK1574","BK1100","159883","BK1597","BK1583","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625935223","title":"昊海生科(688366.SH)子公司多焦点非球面人工晶状体产品获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2625935223","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625935223?lang=zh_cn&edition=full","pubTime":"2026-04-07 16:56","pubTimestamp":1775552194,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生科(688366.SH)发布公告，公司全资子公司河南宇宙人工晶状体研制有限公司于近日收到国家药品监督管理局颁发的关于多焦点非球面人工晶状体产品的《中华人民共和国医疗器械注册证》。该产品是全球首款获批的基于傅里叶谐波五焦点衍射人工晶状体专利技术的多焦点人工晶状体，可实现更高效的光能分配，提高光能利用率，改善传统三焦点人工晶状体的中视力，使远中区域、中距离区域、中近区域的视力更连续平滑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1574","BK0251","159883","BK1100","BK1583","09997","688366","09996","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625841999","title":"山西省药监局：1批医疗器械抽检不合格，涉亚培生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2625841999","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625841999?lang=zh_cn&edition=full","pubTime":"2026-04-07 13:22","pubTimestamp":1775539344,"startTime":"0","endTime":"0","summary":"蓝鲸新闻4月7日讯，山西省药品监督管理局于2026年4月1日发布通告，通报近期对省内医疗器械生产、经营和使用单位开展的监督抽检结果。经检验，共发现1批产品不符合相关强制性标准规定。监管部门已将情况通报被抽样单位及生产企业所在地药监部门，责令立即停止销售使用、排查原因并整改，同时依法立案查处违法行为。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775538736914533840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1583","BK4111","159883","09997","BK1222","BK1574","PSO","BK1100","09996","BK4204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625435984","title":"贵阳星启医疗器械：因未经许可变更生产地址，召回定制式固定义齿","url":"https://stock-news.laohu8.com/highlight/detail?id=2625435984","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625435984?lang=zh_cn&edition=full","pubTime":"2026-04-07 13:22","pubTimestamp":1775539340,"startTime":"0","endTime":"0","summary":"蓝鲸新闻4月7日讯，贵州省药品监督管理局于2026年3月31日通报，贵阳星启医疗器械有限公司因未经许可变更生产地址，主动对所生产的定制式固定义齿（注册证号：黔械注准20252170073）实施三级召回。本次召回涉及多个型号、规格及批次产品，具体信息详见《医疗器械召回事件报告表》。监管部门已责令企业立即停止相关产品销售与使用，并全面开展自查整改；同时要求企业严格落实主体责任，及时向属地监管部门报告召回进展。消费者如已购买相关产品，建议暂停使用并联系企业或经销商处理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775538823911256755","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","159883","09996","BK1100","BK1222","09997","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625198076","title":"每周股票复盘：步长制药（603858）控股子公司完成医疗器械经营许可变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2625198076","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625198076?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:43","pubTimestamp":1775328189,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，步长制药报收于16.43元，较上周的16.3元上涨0.8%。本周，步长制药4月2日盘中最高价报16.96元。步长制药当前最新总市值173.27亿元，在中药板块市值排名14/67，在两市A股市值排名1109/5193。本周关注点来自公司公告汇总：步长制药控股子公司完成医疗器械经营许可证库房地址变更。变更后，企业名称、法定代表人、经营范围、许可期限等信息保持不变。本次变更系基于实际经营需求，对后续生产经营无明显影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","159883","09997","BK1222","603858","BK1574","BK0196","BK1100","09996","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.peijiamedical.com","stockEarnings":[{"period":"1week","weight":0.0847},{"period":"1month","weight":0.1424},{"period":"3month","weight":0.0076},{"period":"6month","weight":0.0521},{"period":"1year","weight":0.4933},{"period":"ytd","weight":0.1082}],"compareEarnings":[{"period":"1week","weight":0.0309},{"period":"1month","weight":-0.0002},{"period":"3month","weight":-0.0129},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.252},{"period":"ytd","weight":0.0103}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"沛嘉医疗有限公司是一家主要提供介入手术医疗器械产品的投资控股公司。该公司主要运营两个业务分部，经导管瓣膜治疗业务分部和神经介入业务分部。经导管瓣膜治疗业务分部主要从事研发、制造及销售经导管瓣膜治疗医疗器械业务。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。该公司的产品包括TaurusOne、TaurusElite等商业化产品。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.057115},{"month":2,"riseRate":0.5,"avgChangeRate":0.017515},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.100991},{"month":4,"riseRate":0.8,"avgChangeRate":0.070327},{"month":5,"riseRate":0.75,"avgChangeRate":-0.061692},{"month":6,"riseRate":0.666667,"avgChangeRate":0.07739},{"month":7,"riseRate":0.5,"avgChangeRate":0.047595},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.086603},{"month":9,"riseRate":0.333333,"avgChangeRate":0.014494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005393},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.027135},{"month":12,"riseRate":0.666667,"avgChangeRate":0.083675}],"exchange":"SEHK","name":"沛嘉医疗-B","nameEN":"PEIJIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沛嘉医疗-B,09996,沛嘉医疗-B股票,沛嘉医疗-B股票老虎,沛嘉医疗-B股票老虎国际,沛嘉医疗-B行情,沛嘉医疗-B股票行情,沛嘉医疗-B股价,沛嘉医疗-B股市,沛嘉医疗-B股票价格,沛嘉医疗-B股票交易,沛嘉医疗-B股票购买,沛嘉医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}